

# Henry Bone

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4419849/henry-bone-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43  
papers

6,183  
citations

33  
h-index

44  
g-index

44  
ext. papers

7,063  
ext. citations

7.4  
avg, IF

5.06  
L-index

#	Paper	IF	Citations
43	Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial. <i>Journal of Bone and Mineral Research</i> , <b>2021</b> , 36, 1225-1234	6.3	2
42	Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. <i>Osteoporosis International</i> , <b>2020</b> , 31, 181-191	5.3	16
41	Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. <i>Current Medical Research and Opinion</i> , <b>2020</b> , 36, 1861-1872	2.5	3
40	Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. <i>Osteoporosis International</i> , <b>2019</b> , 30, 2437-2448	5.3	44
39	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 899-911	18.1	61
38	The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. <i>Osteoporosis International</i> , <b>2019</b> , 30, 71-78	5.3	5
37	Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 1397-1406	6.3	99
36	ACTIVEExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 2949-2957	5.6	90
35	Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. <i>Journal of Bone and Mineral Research</i> , <b>2017</b> , 32, 1481-1485	6.3	17
34	Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation. <i>Osteoporosis International</i> , <b>2017</b> , 28, 1745-1752	5.3	2
33	10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 513-523	18.1	419
32	Denosumab treatment in postmenopausal women with osteoporosis - AuthorsYreply. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 768-769	18.1	4
31	Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study. <i>BMC Musculoskeletal Disorders</i> , <b>2017</b> , 18, 174	2.8	8
30	Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. <i>Osteoporosis International</i> , <b>2015</b> , 26, 699-712	5.3	105
29	The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. <i>Osteoporosis International</i> , <b>2015</b> , 26, 2773-83	5.3	196
28	Hypocalcaemia in patients with metastatic bone disease treated with denosumab. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1812-21	7.5	84
27	The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 4483-92	5.6	202

26	Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 4691-701	5.6	40
25	Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 694-701	6.3	235
24	Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 211-8	6.3	103
23	Future directions in osteoporosis therapeutics. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2012</b> , 41, 655-61	5.5	16
22	Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 2251-8	6.3	125
21	A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 3161-9	5.6	138
20	A single-dose study of denosumab in patients with various degrees of renal impairment. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 1471-9	6.3	208
19	Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 242-51	6.3	196
18	The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 2441-9	5.6	61
17	Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 972-80	5.6	355
16	Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. <i>Bone</i> , <b>2010</b> , 47, 131-9	4.7	68
15	Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. <i>Journal of Bone and Mineral Research</i> , <b>2010</b> , 25, 937-47	6.3	213
14	Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. <i>Journal of Bone and Mineral Research</i> , <b>2010</b> , 25, 72-81	6.3	318
13	Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. <i>Osteoporosis International</i> , <b>2010</b> , 21, 837-46	5.3	40
12	Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. <i>Journal of Bone and Mineral Research</i> , <b>2010</b> , 25, 2256-65	6.3	173
11	Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 118, 81-7	4.4	79
10	Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. <i>Journal of Bone and Mineral Research</i> , <b>2009</b> , 24, 153-61	6.3	399
9	Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. <i>Bone</i> , <b>2009</b> , 45, 833-42	4.7	127

8	Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 2149-57	5.6	290
7	Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 4671-7	5.6	70
6	Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. <i>Bone</i> , <b>2007</b> , 40, 723-9	4.7	93
5	Ten years' experience with alendronate for osteoporosis in postmenopausal women. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 1189-99	59.2	1057
4	Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. <i>Bone</i> , <b>2004</b> , 34, 140-7	4.7	90
3	Study design in osteoporosis: a European perspective. <i>Journal of Bone and Mineral Research</i> , <b>2003</b> , 18, 1133-8	6.3	16
2	Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 720-6	5.6	166
1	Alendronate and Estrogen Effects in Postmenopausal Women with Low Bone Mineral Density. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 720-726	5.6	149